Massachusetts General Hospital and Brigham and Women’s Hospital have placed limits on the outside, institutional pay a number of their senior officials can receive from biotechnology and pharmaceutical companies on whose boards these officials may sit. The decisions were largely dictated by complaints from within and outside the bioindustry and academia over conflict-of-interest issues. Do you think such pay limits represent a good policy move?
Will capping academic consultants’ pay from companies impact academic/industry collaborations?
Yes, these decisions will severely impair the ability of academic institutions and commercial firms to collaborate efficiently and successfully
No, these decisions will not impact such partnerships but will help alleviate concerns about bias and the cost and quality of care that patients might receive at hospitals and medical centers around the U.S.